New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
08:34 EDTIMMUImmunomedics' Epratuzumab in Lupus showed long-term efficacy and safety
Immunomedics announced that patients with moderate-to-severe lupus who had received continued cycles of epratuzumab therapy maintained improvements or further improved their lupus disease activity over a timeframe of approximately 4 years. Importantly, lower levels of median corticosteroid use were also maintained throughout the study. Results from this open-label, single-arm extension study of the Phase III ALLEVIATE trials were reported by clinical investigators at the 2012 American College of Rheumatology Annual Scientific Meeting in Washington DC. Immunomedics has licensed the rights to the development and commercialization of epratuzumab to UCB in all autoimmune diseases.
News For IMMU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
08:50 EDTIMMUImmunomedics reports preliminary results from pretargeted imaging study
Subscribe for More Information
December 12, 2014
08:33 EDTIMMUImmunomedics ADC continues to produce 30% PR rate, 70% CBR
Subscribe for More Information
December 10, 2014
07:46 EDTIMMUOppenheimer to hold a conference
25th Annual Healthcare Conference is being held in New York on December 10-11.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use